Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.54 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12200069 | 0.91 | UTS2R (0.58) | KMT2AMEN1MCHR1SLC6A12TMEM97 | |
| SCHEMBL2387745 | 0.89 | TP53 (0.57) | KMT2AMEN1MCHR1SLC6A12TMEM97 | |
| SCHEMBL2390243 | 0.86 | MEN1 (0.71) | KMT2AMEN1MCHR1SLC6A12TMEM97 | |
| SCHEMBL2388982 | 0.85 | DRD4 (0.64) | KMT2AMEN1MCHR1SLC6A12TMEM97 | |
| SCHEMBL2389917 | 0.84 | MCHR1 (0.70) | KMT2AMEN1MCHR1SLC6A12TMEM97 | |
| SCHEMBL12227453 | 0.84 | POLB (0.61) | KMT2AMEN1MCHR1SLC6A12TMEM97 | |
| SCHEMBL2387674 | 0.84 | POLB (0.64) | KMT2AMEN1MCHR1SLC6A12TMEM97 | |
| SCHEMBL4441428 | 0.84 | SLC6A12 (0.60) | KMT2AMEN1MCHR1SLC6A12TMEM97 | |
| SCHEMBL2390049 | 0.83 | DRD4 (0.67) | KMT2AMEN1MCHR1SLC6A12TMEM97 | |
| SCHEMBL2386397 | 0.83 | SIGMAR1 (0.59) | KMT2AMCHR1SLC6A12TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | KMT2A 634/4885MEN1 4748/4885MCHR1 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.